Core Viewpoint - Inspira Technologies has secured a significant patent for its Convertible Dual Lumen Cannula device in Japan, enhancing its market position in the medical device sector and supporting future commercialization efforts [1][2]. Group 1: Patent and Market Position - The Japan Patent Office granted Patent No. 7777598, providing Inspira exclusive commercial rights for the Dual Lumen Cannula technology in Japan until 2041 [2]. - This patent complements an existing U.S. Patent granted in 2023, creating a protective barrier across two major healthcare markets [2]. - The patented technology allows a single-lumen cannula to convert into a dual-lumen cannula intravascularly, which may reduce infection risks and procedural complications compared to traditional solutions [3]. Group 2: Product and Strategic Implications - The Convertible Dual Lumen Cannula is designed to be a high-value disposable product, potentially enhancing patient safety and procedural efficiency while being more affordable than traditional dual-lumen cannulas [4]. - The company is positioned to benefit from both its respiratory support platforms and future disposable revenue streams due to the proprietary protection in the U.S. and Japan [4]. - Inspira Technologies is advancing its product offerings, including the INSPIRA™ ART100 system for cardiopulmonary bypass and the next-generation INSPIRA ART500 system, which aims to deliver oxygenation while patients remain awake [5].

Core Insights - Inspira Technologies has been granted Patent No. 7777598 by the Japan Patent Office for its Convertible Dual Lumen Cannula device, securing exclusive rights in Japan until 2041, complementing its existing U.S. patent [1][2] - The patented technology allows a single-lumen cannula to convert into a dual-lumen cannula intravascularly after insertion, potentially reducing infection risks and procedural complications compared to traditional solutions [3][4] - The company aims to commercialize the cannula as a high-value disposable product, enhancing patient safety and procedural efficiency while addressing the high manufacturing costs of traditional dual lumen cannulas [4] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with its INSPIRA™ ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [5] - The company is developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake, and advancing the HYLA™ blood sensor platform for continuous, non-invasive monitoring [5] - With a growing IP portfolio and strategic operational streamlining, Inspira Technologies is positioned as an attractive player in the life-support and MedTech landscape, aligning with industry trends such as consolidation and potential strategic partnerships [5]

RA'ANANA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic expansion of its core blood laboratory capabilities, marking a substantial step in the Company's evolution into a broader cutting edge technologies, positioning it for accelerated future growth.The strategic expansion includes transitioning to a substantially ...

Core Insights - Inspira Technologies is expanding its blood laboratory capabilities, transitioning to a larger, state-of-the-art facility to support its growth in blood-based clinical diagnostics and next-generation blood-analysis technologies [1][2][4] Group 1: Strategic Expansion - The strategic expansion includes moving to a larger laboratory, increasing recruitment of specialized personnel, upgrading research instrumentation, and expanding operational capacity [2][3] - The upgraded facility is expected to significantly increase sample processing capacity and integrate advanced capabilities throughout the laboratory [3] Group 2: Commitment to Innovation - This upgrade aims to provide the foundation for Inspira's commitment to innovation, targeting high-value underserved medical needs [4] - The CTO of Inspira Technologies emphasized that this expansion enhances execution capacity and accelerates development, positioning the company for aggressive business growth [5] Group 3: Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products like the INSPIRA™ ART100 system and the upcoming INSPIRA ART500 system [6] - The company is advancing its proprietary blood sensor platform, HYLA™, and is increasingly positioned as an attractive platform within the life-support and MedTech landscape [6]

Core Insights - Inspira Technologies has completed the clinical study for its non-invasive blood sensor, HYLA, and is preparing for regulatory submission and commercialization [1][2][4] - The HYLA sensor demonstrates an accuracy rate between 95% to 99% across various measured parameters, indicating its potential as a disruptive solution for real-time blood monitoring [2][4] - The company is integrating advanced Machine Learning algorithms to enhance the capabilities of the HYLA sensor, aiming to monitor critical physiological parameters not currently available through existing non-invasive systems [3][4] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with its INSPIRA™ ART100 system cleared by the U.S. FDA for cardiopulmonary bypass and ECMO procedures [5] - The company is developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake and breathing spontaneously [5] - With a growing intellectual property portfolio and strategic operational streamlining, Inspira Technologies is positioning itself as an attractive player in the life-support and MedTech sectors [5]

Core Insights - Inspira Technologies has completed the clinical study for its non-invasive blood sensor, HYLA, and is preparing for regulatory submission and commercialization [1][2][4] - The HYLA sensor demonstrates an accuracy rate between 95% to 99% across various measured parameters, indicating its potential as a disruptive solution for real-time blood monitoring [2][4] - The company is integrating advanced Machine Learning algorithms to enhance the capabilities of the HYLA sensor, aiming to monitor critical physiological parameters not currently available through existing non-invasive systems [3][4] Company Overview - Inspira Technologies is a commercial-stage medical device company focused on advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products including the INSPIRA ART100 system [5] - The company is developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake, further expanding its product offerings [5] - Inspira Technologies is positioned as an attractive player in the life-support and MedTech landscape, with a growing intellectual property portfolio and strategic operational streamlining [5]

Core Insights - Inspira Technologies has completed the regulatory submission of its FDA-cleared INSPIRA™ ART100 system to the UAE Ministry of Health and Prevention, with final approval expected imminently, marking a significant step towards commercial entry into the Gulf region [1][2][3] Company Overview - Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, with the INSPIRA™ ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [4] - The company is also developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake and spontaneously breathing, alongside advancing the HYLA™ blood sensor platform for continuous, non-invasive monitoring [4] Regulatory and Market Strategy - The regulatory milestone follows high-level discussions in the UAE, laying the groundwork for potential nationwide deployment and clinical integration of the ART100 system post-approval [2][3] - The UAE is recognized for its efficient and innovation-driven regulatory framework, which is expected to enhance Inspira's regional partnerships and unlock broad commercialization potential across the UAE's healthcare networks [3]

Core Insights - Inspira Technologies has announced a strategic collaboration with Bites Learning Ltd to integrate AI-powered training and performance solutions into its medical device ecosystem [1][2][3] Group 1: Collaboration Details - The collaboration will embed Bites' AI learning platform into Inspira's products, including the INSPIRA™ ART100 and HYLA™ systems, aimed at enhancing training and operational performance [2][3] - This partnership is expected to create an intelligent training layer that simplifies onboarding and standardizes competencies across Inspira's customer base [3][7] Group 2: Expected Benefits - The integration of Bites' AI engine is anticipated to transform medical team training, improve operational consistency, and drive shareholder value [5][7] - The AI-driven platform will provide personalized, real-time knowledge delivery, enhancing the training experience and compliance for users [7][8] Group 3: Future Prospects - The collaboration includes provisions for joint marketing initiatives and potential future strategic transactions, indicating a long-term vision for growth and innovation [7][8] - Inspira Technologies is positioned as an attractive player in the life-support and MedTech landscape, with a focus on advanced respiratory support and real-time blood monitoring solutions [6]

Core Insights - Inspira Technologies has announced a strategic collaboration with Bites Learning Ltd to integrate AI-powered training and performance solutions into its medical device ecosystem [1][2][3] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products like the INSPIRA™ ART100 system for cardiopulmonary bypass and ECMO procedures [6] - The company is developing the INSPIRA ART500, aimed at providing oxygenation while patients remain awake, and advancing the HYLA™ blood sensor platform for continuous monitoring [6] Collaboration Details - The collaboration will embed Bites' AI learning platform into Inspira's products, enhancing training, onboarding, and operational performance for users globally [2][3] - The integration aims to create an intelligent training layer that simplifies onboarding and standardizes competencies across Inspira's customer base [3] Key Features of the Collaboration - AI-Powered Training: Inspira will implement adaptive training modules and digital playbooks for troubleshooting, improving proficiency [7] - Personalized Knowledge Delivery: Bites' AI platform will provide real-time, personalized updates and compliance reminders to users [7] - Data-Driven Analytics: The integrated platform will offer actionable insights on training efficiency and adoption rates, supporting continuous improvement [7] - Built-In Value Layer: Bites' AI capabilities will enhance customer experience and competitive differentiation for Inspira [7] - Joint Marketing and Innovation: Both companies will engage in joint marketing initiatives and co-development of the platform [7] - Long-Term Strategic Options: The collaboration includes provisions for evaluating future strategic transactions or deeper integration [7]

Core Insights - Inspira Technologies has announced a strategic collaboration with Bites Learning Ltd to integrate AI-powered training and performance solutions into its medical device ecosystem [1][2][3] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products including the INSPIRA™ ART100 system for cardiopulmonary bypass and ECMO procedures [6] - The company is developing the INSPIRA ART500, aimed at providing oxygenation while patients remain awake, and advancing the HYLA™ blood sensor platform for continuous monitoring [6] Collaboration Details - The collaboration will embed Bites' AI learning platform into Inspira's products, enhancing training, onboarding, and operational performance for users globally [2][3] - The integration aims to create an intelligent training layer that simplifies onboarding and standardizes competencies across Inspira's customer base [3] Key Features of the Collaboration - AI-Powered Training: Inspira will implement adaptive training modules and digital playbooks for troubleshooting, improving proficiency [7] - Personalized Knowledge Delivery: Bites' AI platform will provide real-time, personalized updates and compliance reminders to users [7] - Data-Driven Analytics: The integrated platform will offer actionable insights on training efficiency and adoption rates, supporting continuous improvement [7] - Built-In Value Layer: Bites' AI capabilities will enhance customer experience and competitive differentiation for Inspira [7] - Joint Marketing Initiatives: Both companies will engage in joint marketing and co-development efforts to foster innovation [7] - Long-Term Strategic Options: The collaboration framework includes evaluating future strategic transactions, highlighting growth potential [7]